Dr. Vincent Dion awarded $250,000 grant to pursue gene editing technology development to find a cure for DM.
The Myotonic Dystrophy Clinical Research Network (DMCRN) sites are currently conducting a critically-important research study designed to help drug developers successfully design clinical trials and understand how to assess the efficacy of potential therapies.
Disorders of sleep and breathing are well characterized for DM1, but what about DM2?
A new review looks at the opportunities and hurdles for genome editing in neuromuscular disease.
Respiratory dysfunction in DM1 draws new attention.